Showing results (211-220 of 286) with videos related to

Sort By:
Pageof 29
BMC Urology|June 4, 2020
Axitinib as a third or further line of treatment in renal cancer: a single institution experienceG Tsironis, M Liontos, A Kyriazoglou, et al.
Human Vaccines|July 10, 2009
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humansKenneth Von Eschen, Royce Morrison, Madeleine Braun, et al.
Cancer Research|June 1, 1992
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screeningL Wu, A M Smythe, S F Stinson, et al.
Vaccine|August 24, 2010
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant SystemsIsabel Leroux-Roels, Marguerite Koutsoukos, Frédéric Clement, et al.
Clinical and Vaccine Immunology : CVI|September 24, 2010
Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adultsIsabel Leroux-Roels, Geert Leroux-Roels, Opokua Ofori-Anyinam, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Scientific Data|October 9, 2025
Multiomics analysis of the Silkworm cocoon shellPanagiota Fragkou, Ioannis Martakos, Georgia Rouni, et al.
Science (New York, N.Y.)|October 16, 1992
Neural computing in cancer drug development: predicting mechanism of actionJ N Weinstein, K W Kohn, M R Grever, et al.
Gynecologic Oncology|March 17, 2020
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapyMichalis Liontos, Maria Sotiropoulou, Maria Kaparelou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 27, 2012
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapyKaren Kelly, Christopher G Azzoli, Petr Zatloukal, et al.
Pageof 29